Form 8-K - Current report:
SEC Accession No. 0001193125-25-061426
Filing Date
2025-03-24
Accepted
2025-03-24 17:02:24
Documents
17
Period of Report
2025-03-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d943621d8k.htm   iXBRL 8-K 34420
2 EX-10.1 d943621dex101.htm EX-10.1 49490
3 EX-10.2 d943621dex102.htm EX-10.2 87285
7 GRAPHIC g943621g0324214339992.jpg GRAPHIC 21392
8 GRAPHIC g943621g0324214340294.jpg GRAPHIC 26158
  Complete submission text file 0001193125-25-061426.txt   411554

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apto-20250318.xsd EX-101.SCH 2878
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apto-20250318_lab.xml EX-101.LAB 19469
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apto-20250318_pre.xml EX-101.PRE 12163
19 EXTRACTED XBRL INSTANCE DOCUMENT d943621d8k_htm.xml XML 3938
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 25764959
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)